Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders for Alnylam Pharmaceuticals, Inc., held on May 16, 2024. The report details the outcomes of shareholder votes regarding director elections, executive compensation, and auditor ratification.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance events.
Material Changes
There are no material financial changes reported in this filing. The primary events are the re-election of Class II directors and the approval of executive compensation and auditor appointment.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. It strictly summarizes the voting results of the Annual Meeting.
Important Facts for Investors
- Director Elections: Stockholders re-elected four Class II directors (Dennis A. Ausiello, Olivier Brandicourt, Peter N. Kellogg, and David E.I. Pyott) to serve until the 2027 annual meeting.
- Executive Compensation: The non-binding advisory vote on executive compensation was approved with 106,783,262 votes for and 6,133,628 votes against.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2024.
- Share Count: As of the record date (March 22, 2024), 126,452,099 shares of common stock were issued and outstanding.